文献速递泌尿男性生殖肿瘤

精准医学时代的肾细胞癌:从分子病理到组织生物标志物

Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers.
PubMed 文献 · J Clin Oncol · 2018-10-29

肾细胞癌(RCC)并非单一疾病,而是基于病理特征或分子改变区分的多种亚型。透明细胞RCC最常见,特征为VHL/HIF通路失调;非透明细胞RCC异质性更强。近二十年来对RCC分子景观的理解促进了靶向药物和免疫检查点抑制剂等转移性RCC治疗的发展,但仅部分患者应答,亟需预测性生物标志物指导治疗选择与序贯。本文综述RCC亚型的关键组织学与分子改变,并讨论现有转移性RCC治疗应答的新兴组织生物标志物。

要点

  • RCC包含多种亚型,透明细胞RCC以VHL/HIF通路失调为特征。
  • 非透明细胞RCC组织病理与分子特征异质性更强。
  • 转移性RCC治疗包括靶向药物和免疫检查点抑制剂,但仅部分患者应答。

核心结论

  • RCC亚型基于病理特征或分子改变区分,透明细胞RCC特征为VHL/HIF通路失调。
  • 转移性RCC治疗包括靶向药物和免疫检查点抑制剂,但仅部分患者应答,需要预测性生物标志物指导治疗选择与序贯。

研究设计与样本

  • 本文为综述,描述RCC亚型的关键组织学特征和分子改变,并讨论现有转移性RCC治疗应答的新兴组织生物标志物。

主要发现

  • 透明细胞RCC是最常见类型,以VHL/HIF通路失调为特征。
  • 非透明细胞RCC是更具异质性的肿瘤组,具有多样的组织病理学和分子特征。
  • 近二十年来对RCC分子景观的深入理解促进了更有效的转移性RCC治疗的发展,包括靶向药物和免疫检查点抑制剂。

临床怎么用

  • 基于RCC亚型的组织学与分子特征理解,有助于选择靶向治疗或免疫检查点抑制剂。
  • 组织生物标志物有望指导转移性RCC的治疗选择与序贯。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Renal cell carcinoma (RCC) is not a single entity but includes various tumor subtypes that have been identified on the basis of either characteristic pathologic features or distinctive molecular changes. Clear cell RCC is the most common type of RCC and is characterized by dysregulation of the von Hippel Lindau/hypoxia-inducible factor pathway. Non-clear cell RCC represents a more heterogeneous group of tumors with diverse histopathologic and molecular features. In the past two decades, the improved understanding of the molecular landscape of RCC has led to the development of more effective therapies for metastatic RCC, which include both targeted agents and immune checkpoint inhibitors. Because only subsets of patients with metastatic RCC respond to a given treatment, predictive biomarkers are needed to guide treatment selection and sequence. In this review, we describe the key histologic features and molecular alterations of RCC subtypes and discuss emerging tissue-based biomarkers of response to currently available therapies for metastatic disease.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Signoretti S, Flaifel A, Chen YB, et al. Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. J Clin Oncol. 2018. PMID: 30372384. doi:10.1200/JCO.2018.79.2259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。